Is Collegium Pharmaceutical, Inc. (COLL) the Best Small Cap Pharma Stocks to Buy Now?

Collegium Pharmaceutical, Inc. (COLL) has emerged as a strong contender in the small cap pharmaceutical sector, with its robust financial performance and strategic growth initiatives. The company's focus on abuse-deterrent, extended-release, and oral formulations of opioids for pain management, as well as its expansion into the ADHD market, has positioned it competitively in the pharmaceutical industry. In this article, we will explore the reasons why Collegium Pharmaceutical, Inc. (COLL) could be the best small cap pharma stock to buy now.

Strong Financial Performance

Collegium Pharmaceutical reported record quarterly and full-year net revenue of $181.9 million and $631.4 million, respectively, in 2024. This represents a 22% increase year-over-year for the quarter and an 11% increase for the full year (Collegium Pharmaceutical, Inc. Q4 2024 Earnings Call Transcript, February 27, 2025). The company's adjusted EBITDA grew by 3% year-over-year for the quarter and 9% for the full year, reaching $107.7 million for Q4 and $401.2 million for the full year, respectively. This underlying operational strength supports Collegium Pharmaceutical's financial growth and positions it as a strong investment opportunity.

Strategic Growth Initiatives

Collegium Pharmaceutical's acquisition of Ironshore Therapeutics and its lead medicine, Jornay PM, has proven successful. With prescriptions growing 29% year over year and 11% quarter over quarter, Jornay PM has shown strong market acceptance and positions Collegium as a significant player in the competitive ADHD landscape. The delayed-release evening dosing formulation of Jornay PM differentiates it from established players and generics, providing a unique treatment option for patients and healthcare providers.

Collegium's strategic diversification into ADHD, neuropsychiatry, and broader CNS areas has reduced concentration risk and targeted complementary growth markets that leverage the company's commercial infrastructure. This balanced approach has allowed Collegium to maintain focus on its core portfolio while expanding into new therapeutic areas, creating operational synergies and providing strategic diversification benefits.

Competitive Landscape

Collegium Pharmaceutical's product portfolio, particularly its pain management and ADHD treatments, positions it competitively in the pharmaceutical industry. The company's focus on abuse-deterrent, extended-release, and oral formulations of opioids for pain management has allowed it to maintain a strong market position despite regulatory scrutiny on prescribing patterns. These products have demonstrated record revenues and prescription growth, outpacing the broader pain management market.

In the ADHD market, Collegium's acquisition of Ironshore Therapeutics and its lead medicine, Jornay PM, has proven successful. With prescriptions growing 29% year over year and 11% quarter over quarter, Jornay PM has shown strong market acceptance and positions Collegium as a significant player in the competitive ADHD landscape. The delayed-release evening dosing formulation of Jornay PM differentiates it from established players and generics, providing a unique treatment option for patients and healthcare providers.

Conclusion

Collegium Pharmaceutical, Inc. (COLL) has demonstrated strong financial performance and strategic growth initiatives, positioning it as a leading contender in the small cap pharmaceutical sector. The company's focus on abuse-deterrent, extended-release, and oral formulations of opioids for pain management, as well as its expansion into the ADHD market, has allowed it to maintain a competitive edge in the pharmaceutical industry. With its robust financial performance and strategic growth initiatives, Collegium Pharmaceutical, Inc. (COLL) could be the best small cap pharma stock to buy now.